Submissions for variant NM_000535.7(PMS2):c.58C>G (p.Arg20Gly)

dbSNP: rs573374779

Total submissions: 6

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Labcorp Genetics (formerly Invitae), Labcorp	RCV000468998	SCV000552068	likely benign	Hereditary nonpolyposis colorectal neoplasms	2024-12-16	criteria provided, single submitter	clinical testing
Ambry Genetics	RCV000561984	SCV000663457	uncertain significance	Hereditary cancer-predisposing syndrome	2024-02-09	criteria provided, single submitter	clinical testing	The p.R20G variant (also known as c.58C>G), located in coding exon 2 of the PMS2 gene, results from a C to G substitution at nucleotide position 58. The arginine at codon 20 is replaced by glycine, an amino acid with dissimilar properties. This alteration has been reported in a cohort of 488 patients with stages I to III breast cancer diagnosed over age 50 who were tested with a 25-gene panel test (Tung N et al. J. Clin. Oncol., 2016 May;34:1460-8). This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Color Diagnostics, LLC DBA Color Health	RCV000561984	SCV001341288	uncertain significance	Hereditary cancer-predisposing syndrome	2020-03-11	criteria provided, single submitter	clinical testing	This missense variant replaces arginine with glycine at codon 20 of the PMS2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). Splice site prediction tools suggest that this variant may not impact RNA splicing. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with breast cancer (PMID: 26976419). This variant has been identified in 2/245594 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
GeneDx	RCV002289614	SCV002578785	uncertain significance	not provided	2022-11-30	criteria provided, single submitter	clinical testing	Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 11574484, 26976419)
All of Us Research Program, National Institutes of Health	RCV004001884	SCV004842176	uncertain significance	Lynch syndrome	2024-07-10	criteria provided, single submitter	clinical testing	This missense variant replaces arginine with glycine at codon 20 of the PMS2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). Splice site prediction tools suggest that this variant may not impact RNA splicing. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with breast cancer (PMID: 26976419). This variant has been identified in 2/245594 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Clinical Genetics Laboratory, Skane University Hospital Lund	RCV002289614	SCV005197213	uncertain significance	not provided	2022-06-03	criteria provided, single submitter	clinical testing